Bisoprolol ve hidroklorotiyazid etkileşimleri

beta bloker sınıfından Bisoprolol ve hidroklorotiyazid (Ziac) için dizinlediğimiz FDA etiketlerinde ve bilgi sayfalarında 476 belgelenmiş etkileşim var: 43 majör, 373 orta, 57 minör ve bir etiketin anlamlı etkileşim olmadığını bildirdiği 3 çift. Aşağıdaki her kayıt, dayandığı cümleyi alıntılar. Bu ilaç sayfası bir başlangıç noktasıdır; sizin durumunuz için verilmiş bir hüküm değildir.

Bisoprolol ve hidroklorotiyazid nasıl görünür

24 sürümün tümü
Bisoprolol ve hidroklorotiyazid 6.25 mg / 5 mg tablet: pembe, yuvarlak, 8 mm, bir yüzünde UL, diğer yüzünde ll baskısı var.
UL / ll
6.25 mg / 5 mg · pembe · yuvarlak · 8 mm
Unichem Pharmaceuticals (U…
Bisoprolol ve hidroklorotiyazid 2.5 mg / 6.25 mg tablet: sarı, yuvarlak, 7 mm, üzerinde 113 baskısı var.
113
2.5 mg / 6.25 mg · sarı · yuvarlak · 7 mm
Viona
Bisoprolol ve hidroklorotiyazid 5 mg / 6.25 mg tablet: pembe, yuvarlak, 7 mm, üzerinde 114 baskısı var.
114
5 mg / 6.25 mg · pembe · yuvarlak · 7 mm
Viona
Bisoprolol ve hidroklorotiyazid 10 mg / 6.25 mg tablet: beyaz, yuvarlak, 7 mm, üzerinde 115 baskısı var.
115
10 mg / 6.25 mg · beyaz · yuvarlak · 7 mm
Viona

Çizimler, FDA etiketlerindeki ürün bilgilerinden oluşturulmuştur: renk, şekil, boyut ve baskı. 10 firmaya ait 24 belgelenmiş sürüm.

Etikete göre etkileşimler

Majör etkileşimler (43)

  • Amiloridpotasyum tutucu diüretikMajör

    Hyperkalemia occurs commonly (about 10%) when amiloride is used without a kaliuretic diuretic. (Amilorid etiketi, Kutulu uyarı)

  • Arsenik trioksitQT aralığını uzatan ilaçMajör

    The risk of torsade de pointes is related to the extent of QTc prolongation, concomitant administration of QTc prolonging drugs, a history of torsade de pointes, pre-existing QTc interval prolongation, congestive heart failure, administration of potassium-wasting diuretics, or other conditions that result in hypokalemia or hypomagnesemia. (Arsenik trioksit etiketi, Uyarılar ve önlemler)

  • Asetazolamidkarbonik anhidraz inhibitörüMajör

    CONTRAINDICATIONS Bisoprolol fumarate and hydrochlorothiazide tablets are contraindicated in patients in cardiogenic shock, overt cardiac failure (see WARNINGS ), second or third degree AV block, marked sinus bradycardia, anuria, and hypersensitivity to either component of this product or to other sulfonamide-derived drugs. (Bisoprolol ve hidroklorotiyazid etiketi, Kontrendikasyonlar)

  • Benazepril ve hidroklorotiyazidACE inhibitörüMajör

    Lotensin HCT is also contraindicated in patients who are hypersensitive to benazepril, to any other ACE inhibitor, to hydrochlorothiazide, or to other sulfonamide-derived drugs. (Benazepril ve hidroklorotiyazid etiketi, Kontrendikasyonlar)

  • Brinzolamidkarbonik anhidraz inhibitörüMajör

    CONTRAINDICATIONS Bisoprolol fumarate and hydrochlorothiazide tablets are contraindicated in patients in cardiogenic shock, overt cardiac failure (see WARNINGS ), second or third degree AV block, marked sinus bradycardia, anuria, and hypersensitivity to either component of this product or to other sulfonamide-derived drugs. (Bisoprolol ve hidroklorotiyazid etiketi, Kontrendikasyonlar)

  • Bumetanidkıvrım (loop) diüretiğiMajör

    WARNING Bumetanide is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion. (Bumetanid etiketi, Kutulu uyarı)

  • DiazoksitMajör

    CONTRAINDICATIONS PROGLYCEM is contraindicated in patients with: Functional hypoglycemia Hypersensitivity to diazoxide, any of the excipients in PROGLYCEM, or other thiazides (Diazoksit etiketi, Kontrendikasyonlar)

  • Diklorfenamidkarbonik anhidraz inhibitörüMajör

    CONTRAINDICATIONS Bisoprolol fumarate and hydrochlorothiazide tablets are contraindicated in patients in cardiogenic shock, overt cardiac failure (see WARNINGS ), second or third degree AV block, marked sinus bradycardia, anuria, and hypersensitivity to either component of this product or to other sulfonamide-derived drugs. (Bisoprolol ve hidroklorotiyazid etiketi, Kontrendikasyonlar)

  • DofetilidantiaritmikMajör

    The concomitant use of hydrochlorothiazide (alone or in combinations such as with triamterene) with dofetilide is contraindicated (see PRECAUTIONS, Drug-Drug Interactions ) because this has been shown to significantly increase dofetilide plasma concentrations and QT interval prolongation. (Dofetilid etiketi, Kontrendikasyonlar)

  • Dorzolamidkarbonik anhidraz inhibitörüMajör

    CONTRAINDICATIONS Bisoprolol fumarate and hydrochlorothiazide tablets are contraindicated in patients in cardiogenic shock, overt cardiac failure (see WARNINGS ), second or third degree AV block, marked sinus bradycardia, anuria, and hypersensitivity to either component of this product or to other sulfonamide-derived drugs. (Bisoprolol ve hidroklorotiyazid etiketi, Kontrendikasyonlar)

  • Dorzolamid ve timololkarbonik anhidraz inhibitörüMajör

    CONTRAINDICATIONS Bisoprolol fumarate and hydrochlorothiazide tablets are contraindicated in patients in cardiogenic shock, overt cardiac failure (see WARNINGS ), second or third degree AV block, marked sinus bradycardia, anuria, and hypersensitivity to either component of this product or to other sulfonamide-derived drugs. (Bisoprolol ve hidroklorotiyazid etiketi, Kontrendikasyonlar)

  • Droperidoldopamin antagonistiMajör

    Droperidol should be administered with extreme caution to patients who may be at risk for development of prolonged QT syndrome (e.g., congestive heart failure, bradycardia, use of a diuretic, cardiac hypertrophy, hypokalemia, hypomagnesemia, or administration of other drugs known to increase the QT interval). (Droperidol etiketi, Kutulu uyarı)

  • EnalaprilatACE inhibitörüMajör

    …sometimes associated with oliguria and/or progressive azotemia, and rarely with acute renal failure and/or death, include those with the following conditions or characteristics: heart failure, hyponatremia, high dose diuretic therapy, recent intensive diuresis or increase in diuretic dose, renal dialysis, or severe volume and/or salt depletion of any etiology. (Enalaprilat etiketi, Uyarılar)

  • Eplerenonaldosteron antagonistiMajör

    …• serum creatinine > 2.0 mg/dL in males or >1.8 mg/dL in females, • creatinine clearance < 50 mL/min, or • concomitant administration of potassium supplements or potassium-sparing diuretics (e.g., amiloride, spironolactone, or triamterene) [see Warnings and Precautions (5.1) , Adverse Reactions (6.2) , Drug Interactions (7) , and Clinical Pharmacology (12.3)… (Eplerenon etiketi, Kontrendikasyonlar)

  • Eptifibatidantitrombosit ilaçMajör

    …of active abnormal bleeding within the previous 30 days Severe hypertension (systolic blood pressure >200 mm Hg or diastolic blood pressure >110 mm Hg) not adequately controlled on antihypertensive therapy Major surgery within the preceding 6 weeks History of stroke within 30 days or any history of hemorrhagic stroke Current or planned administration of another… (Eptifibatid etiketi, Kontrendikasyonlar)

  • Etakrinik asitkıvrım (loop) diüretiğiMajör

    CONTRAINDICATIONS All diuretics, including ethacrynic acid, are contraindicated in anuria. (Etakrinik asit etiketi, Kontrendikasyonlar)

  • FlekainidantiaritmikMajör

    Concomitant negative chronotropic therapy such as digoxin or beta-blockers may lower the risk of this complication. (Flekainid etiketi, Kutulu uyarı)

  • Because the use of diuretics can accentuate the diminished intravascular volume, diuretics should be avoided except in the late phase of resolution as described below. (Follitropin etiketi, Uyarılar ve önlemler)

  • GentamisinaminoglikozidMajör

    The concurrent use of gentamicin with potent diuretics, such as ethacrynic acid or furosemide, should be avoided, since certain diuretics by themselves may cause ototoxicity. (Gentamisin etiketi, Kutulu uyarı)

  • Gümüş sülfadiazinsülfonamidMajör

    CONTRAINDICATIONS Bisoprolol fumarate and hydrochlorothiazide tablets are contraindicated in patients in cardiogenic shock, overt cardiac failure (see WARNINGS ), second or third degree AV block, marked sinus bradycardia, anuria, and hypersensitivity to either component of this product or to other sulfonamide-derived drugs. (Bisoprolol ve hidroklorotiyazid etiketi, Kontrendikasyonlar)

  • Avoid diuretics or laxatives in patients with diarrhea. (İrinotekan etiketi, Uyarılar ve önlemler)

  • İtrakonazolazol antifungalMajör

    Diuretics Eplerenone Contraindicated during and 2 weeks after TOLSURA treatment. (İtrakonazol etiketi, İlaç etkileşimleri)

  • KinaprilACE inhibitörüMajör

    …sometimes associated with oliguria and/or progressive azotemia, and rarely with acute renal failure and/or death, include patients with the following conditions or characteristics: heart failure, hyponatremia, high dose diuretic therapy, recent intensive diuresis or increase in diuretic dose, renal dialysis, or severe volume and/or salt depletion of any etiology. (Kinapril etiketi, Uyarılar)

  • KlozapinantipsikotikMajör

    Use CLOZARIL cautiously in patients with cardiovascular or cerebrovascular disease or conditions predisposing to hypotension (e.g., dehydration, use of antihypertensive medications) [see Dosage and Administration ( 2.2 , 2.6 ), Warnings and Precautions ( 5.2 )]. (Klozapin etiketi, Kutulu uyarı)

  • Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (Koriogonadotropin alfa etiketi, Uyarılar)

  • Metazolamidkarbonik anhidraz inhibitörüMajör

    CONTRAINDICATIONS Bisoprolol fumarate and hydrochlorothiazide tablets are contraindicated in patients in cardiogenic shock, overt cardiac failure (see WARNINGS ), second or third degree AV block, marked sinus bradycardia, anuria, and hypersensitivity to either component of this product or to other sulfonamide-derived drugs. (Bisoprolol ve hidroklorotiyazid etiketi, Kontrendikasyonlar)

  • MetirozinMajör

    In addition, life-threatening arrhythmias may occur during anesthesia and surgery, and may require treatment with a beta-blocker or lidocaine. (Metirozin etiketi, Uyarılar)

  • Metolazontiyazid diüretikMajör

    Other Antihypertensive Drugs When metolazone tablets, USP, are used with other antihypertensive drugs, particular care must be taken to avoid excessive reduction of blood pressure, especially during initial therapy. (Metolazon etiketi, Uyarılar)

  • MinoksidilvazodilatörMajör

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (Minoksidil etiketi, Kutulu uyarı)

  • Nebivololbeta blokerMajör

    Hypotensive Agents Do not use BYSTOLIC with other β-blockers. (Nebivolol etiketi, İlaç etkileşimleri)

  • NeomisinaminoglikozidMajör

    The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. (Neomisin etiketi, Kutulu uyarı)

  • Potasyum sitratpotasyum takviyesiMajör

    The following drug interactions may occur with potassium citrate: Potassium-sparing diuretics: concomitant administration should be avoided since the simultaneous administration of these agents can produce severe hyperkalemia (7.1) (Potasyum sitrat etiketi, İlaç etkileşimleri)

  • ProtaminMajör

    Risk factors include high dose or overdose, rapid administration (see WARNINGS and DOSAGE AND ADMINISTRATION ), repeated doses, previous administration of protamine, and current or previous use of protamine-containing drugs (NPH insulin, protamine zinc insulin, and certain beta-blockers). (Protamin etiketi, Kutulu uyarı)

  • RepaglinidmeglitinidMajör

    Examples: beta-blockers, clonidine, guanethidine, and reserpine Clopidogrel : Avoid concomitant use; if used concomitantly initiate at 0.5 mg before each meal and limit total daily dose to 4 mg ( 7 ) (Repaglinid etiketi, İlaç etkileşimleri)

  • Rivastigminkolinesteraz inhibitörüMajör

    Concomitant use with metoclopramide, beta-blockers, or cholinomimetic and anticholinergic drugs is not recommended ( 7.1 , 7.2 , 7.3 ) (Rivastigmin etiketi, İlaç etkileşimleri)

  • SiklosporinimmünosüpresanMajör

    Potassium-Sparing Diuretics Cyclosporine should not be used with potassium-sparing diuretics because hyperkalemia can occur. (Siklosporin etiketi, İlaç etkileşimleri)

  • Sodyum bikarbonatantasitMajör

    Sodium bicarbonate injection is contraindicated in patients who are losing chloride by vomiting or from continuous gastrointestinal suction and in patients receiving diuretics known to produce a hypochloremic alkalosis. (Sodyum bikarbonat etiketi, Kontrendikasyonlar)

  • SülfadiazinsülfonamidMajör

    CONTRAINDICATIONS Bisoprolol fumarate and hydrochlorothiazide tablets are contraindicated in patients in cardiogenic shock, overt cardiac failure (see WARNINGS ), second or third degree AV block, marked sinus bradycardia, anuria, and hypersensitivity to either component of this product or to other sulfonamide-derived drugs. (Bisoprolol ve hidroklorotiyazid etiketi, Kontrendikasyonlar)

  • CONTRAINDICATIONS Bisoprolol fumarate and hydrochlorothiazide tablets are contraindicated in patients in cardiogenic shock, overt cardiac failure (see WARNINGS ), second or third degree AV block, marked sinus bradycardia, anuria, and hypersensitivity to either component of this product or to other sulfonamide-derived drugs. (Bisoprolol ve hidroklorotiyazid etiketi, Kontrendikasyonlar)

  • SülfasalazinsülfonamidMajör

    CONTRAINDICATIONS Bisoprolol fumarate and hydrochlorothiazide tablets are contraindicated in patients in cardiogenic shock, overt cardiac failure (see WARNINGS ), second or third degree AV block, marked sinus bradycardia, anuria, and hypersensitivity to either component of this product or to other sulfonamide-derived drugs. (Bisoprolol ve hidroklorotiyazid etiketi, Kontrendikasyonlar)

  • TadalafilPDE5 inhibitörüMajör

    …coadministration of an alpha-blocker and CIALIS for the treatment of BPH has not been adequately studied, and due to the potential vasodilatory effects of combined use resulting in blood pressure lowering, the combination of CIALIS and alpha-blockers is not recommended for the treatment of BPH. [see Dosage and Administration ( 2.7 ), Drug Interactions ( 7.1 ),… (Tadalafil etiketi, Uyarılar ve önlemler)

  • TranilsiprominMAO inhibitörüMajör

    …Syndrome (SS) c ] Agents with blood pressure-reducing effects Use with caution d Hypotension e Non-selective H1 receptor antagonists Contraindicated a Increased anticholinergic effects Beta-adrenergic blockers (see also agents or procedures with blood pressure-reducing effects) Use with the caution d More pronounced bradycardia, postural hypotension e Blood glucose-lowering… (Tranilsipromin etiketi, İlaç etkileşimleri)

  • ZonisamidantikonvülsanMajör

    CONTRAINDICATIONS Bisoprolol fumarate and hydrochlorothiazide tablets are contraindicated in patients in cardiogenic shock, overt cardiac failure (see WARNINGS ), second or third degree AV block, marked sinus bradycardia, anuria, and hypersensitivity to either component of this product or to other sulfonamide-derived drugs. (Bisoprolol ve hidroklorotiyazid etiketi, Kontrendikasyonlar)

Orta düzey etkileşimler (373)

  • AdenozinantiaritmikOrta

    Bisoprolol fumarate and hydrochlorothiazide tablets should be used with caution when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently. (Bisoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

  • AdrenalinsempatomimetikOrta

    Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reactions. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • AkarbozantidiyabetikOrta

    Antidiabetic drugs (oral agents and insulin) - dosage adjustment of the antidiabetic drug may be required. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Alfuzosinalfa blokerOrta

    Postural hypotension/syncope: Care should be taken in patients with symptomatic hypotension or who have had a hypotensive response to other medications or are concomitantly treated with antihypertensive medication or nitrates ( 5.1 ) (Alfuzosin etiketi, Uyarılar ve önlemler)

  • AliskirenantihipertansifOrta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • AlkolAlkolOrta

    Alcohol, barbiturates, or narcotics - potentiation of orthostatic hypotension may occur. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Allopurinolksantin oksidaz inhibitörüOrta

    Hypersensitivity reactions to allopurinol tablets may be increased in patients with decreased kidney function receiving thiazide diuretics and allopurinol tablets concurrently. (Allopurinol etiketi, Uyarılar ve önlemler)

  • AlogliptinDPP-4 inhibitörüOrta

    Antidiabetic drugs (oral agents and insulin) - dosage adjustment of the antidiabetic drug may be required. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Alogliptin ve metforminDPP-4 inhibitörüOrta

    Antidiabetic drugs (oral agents and insulin) - dosage adjustment of the antidiabetic drug may be required. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • AmikasinaminoglikozidOrta

    Ethacrynic Acid, Furosemide, Urea, or Mannitol Some diuretics can enhance aminoglycoside toxicity by altering aminoglycoside concentrations in serum and tissue. (Amikasin etiketi, İlaç etkileşimleri)

  • AmiodaronantiaritmikOrta

    Bisoprolol fumarate and hydrochlorothiazide tablets should be used with caution when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently. (Bisoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

  • Amlodipindihidropiridin kalsiyum kanal blokeriOrta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • Amlodipin ve atorvastatindihidropiridin kalsiyum kanal blokeriOrta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • Amlodipin ve benazeprildihidropiridin kalsiyum kanal blokeriOrta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • Amlodipin ve olmesartandihidropiridin kalsiyum kanal blokeriOrta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • Amlodipin ve valsartandihidropiridin kalsiyum kanal blokeriOrta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • Amoksisilinpenisilin antibiyotikOrta

    Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • Amoksisilin ve klavulanatpenisilin antibiyotikOrta

    Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • Ampisilinpenisilin antibiyotikOrta

    Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • Ampisilin ve sulbaktampenisilin antibiyotikOrta

    Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • Arformoterolbeta adrenerjik agonistOrta

    Xanthine derivatives, steroids, diuretics, or non-potassium sparing diuretics may potentiate hypokalemia or ECG changes. (Arformoterol etiketi, İlaç etkileşimleri)

  • AripiprazolantipsikotikOrta

    Antihypertensive Drugs Due to its alpha-adrenergic antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive agents. (Aripiprazol etiketi, İlaç etkileşimleri)

  • ArmodafinilMSS uyarıcısıOrta

    There was also a slightly greater proportion of patients on NUVIGIL requiring new or increased use of antihypertensive medications (2.9%) compared to patients on placebo (1.8%). (Armodafinil etiketi, Uyarılar ve önlemler)

  • Artikain ve adrenalinlokal anestezikOrta

    Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reactions. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Asebutololbeta blokerOrta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • AsenapinantipsikotikOrta

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medications, patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities), and patients… (Asenapin etiketi, Uyarılar ve önlemler)

  • AspirinNSAİİOrta

    Nonsteroidal anti-inflammatory drugs - In some patients, the administration of a nonsteroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium sparing, and thiazide diuretics. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Aspirin ve dipiridamolantitrombosit ilaçOrta

    Nonsteroidal anti-inflammatory drugs - In some patients, the administration of a nonsteroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium sparing, and thiazide diuretics. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Atenololbeta blokerOrta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • Atomoksetinnoradrenalin geri alım inhibitörüOrta

    Antihypertensive Drugs Prevention or Management Increase the frequency of monitoring blood pressure and adjust atomoxetine oral solution dosage as clinically appropriate. (Atomoksetin etiketi, İlaç etkileşimleri)

  • AvanafilPDE5 inhibitörüOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • Azilsartananjiyotensin II reseptör blokeri (ARB)Orta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • Baklofenkas gevşeticiOrta

    Skeletal muscle relaxants, nondepolarizing (e.g., tubocurarine) - possible increased responsiveness to the muscle relaxant. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • BeksagliflozinSGLT2 inhibitörüOrta

    Antidiabetic drugs (oral agents and insulin) - dosage adjustment of the antidiabetic drug may be required. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Alcohol, barbiturates, or narcotics - potentiation of orthostatic hypotension may occur. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • BenazeprilACE inhibitörüOrta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • BenzfetaminMSS uyarıcısıOrta

    Amphetamines may decrease the hypotensive effect of antihypertensives. (Benzfetamin etiketi, İlaç etkileşimleri)

  • Betaksololbeta blokerOrta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • Bisoprololbeta blokerOrta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • BrekspiprazolantipsikotikOrta

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (Brekspiprazol etiketi, Uyarılar ve önlemler)

  • Brimonidinalfa adrenerjik agonistOrta

    Antihypertensives/Cardiac Glycosides Because brimonidine tartrate ophthalmic solution 0.1% and 0.15% may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with brimonidine tartrate ophthalmic solution 0.1% and 0.15% is advised. (Brimonidin etiketi, İlaç etkileşimleri)

  • Brimonidin ve timololalfa adrenerjik agonistOrta

    Antihypertensives/Cardiac Glycosides Because brimonidine tartrate/timolol maleate ophthalmic solution may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with brimonidine tartrate/timolol maleate ophthalmic solution is advised. (Brimonidin ve timolol etiketi, İlaç etkileşimleri)

  • Central Nervous System (CNS) depressants Antihistamines have additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, antianxiety agents, etc.). Antihypertensive drugs Sympathomimetic may reduce the effects of antihypertensive drugs. (Bromfeniramin, psödoefedrin ve dekstrometorfan etiketi, İlaç etkileşimleri)

  • Bromokriptindopamin agonistiOrta

    Use caution in patients taking antihypertensive medications. (Bromokriptin etiketi, Uyarılar ve önlemler)

  • Budesonid ve formoterolkortikosteroidOrta

    Beta-blockers: Use with caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

  • Bupivakainlokal anestezikOrta

    Risk of Hypertension and Bradycardia Due to Drug Interactions Between MARCAINE WITH EPINEPHRINE and Nonselective Beta-Adrenergic Antagonists Administration of MARCAINE WITH EPINEPHRINE (containing a vasoconstrictor) in patients receiving nonselective beta-adrenergic antagonists may cause severe hypertension and bradycardia. (Bupivakain etiketi, Uyarılar ve önlemler)

  • Bupivakain ve adrenalinlokal anestezikOrta

    Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reactions. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • BuprenorfinopioidOrta

    Alcohol, barbiturates, or narcotics - potentiation of orthostatic hypotension may occur. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Alcohol, barbiturates, or narcotics - potentiation of orthostatic hypotension may occur. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • BupropionantidepresanOrta

    Drugs Metabolized by CYP2D6: Bupropion inhibits CYP2D6 and can increase concentrations of: antidepressants (e.g., venlafaxine, nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide). (Bupropion etiketi, İlaç etkileşimleri)

  • Alcohol, barbiturates, or narcotics - potentiation of orthostatic hypotension may occur. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Alcohol, barbiturates, or narcotics - potentiation of orthostatic hypotension may occur. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Alcohol, barbiturates, or narcotics - potentiation of orthostatic hypotension may occur. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Alcohol, barbiturates, or narcotics - potentiation of orthostatic hypotension may occur. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Alcohol, barbiturates, or narcotics - potentiation of orthostatic hypotension may occur. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • ButorfanolopioidOrta

    Alcohol, barbiturates, or narcotics - potentiation of orthostatic hypotension may occur. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • D vitaminiVitamin ve mineralOrta

    Tiyazid diüretikler kalsiyum atılımını azaltır; D vitamini ve kalsiyum takviyeleriyle birlikte bu durum, özellikle yaşlı yetişkinlerde hiperkalsemiye yol açabilir. (NIH Office of Dietary Supplements, Vitamin D)

  • Dantrolenkas gevşeticiOrta

    Skeletal muscle relaxants, nondepolarizing (e.g., tubocurarine) - possible increased responsiveness to the muscle relaxant. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • DapagliflozinSGLT2 inhibitörüOrta

    Antidiabetic drugs (oral agents and insulin) - dosage adjustment of the antidiabetic drug may be required. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Dapagliflozin ve metforminSGLT2 inhibitörüOrta

    Antidiabetic drugs (oral agents and insulin) - dosage adjustment of the antidiabetic drug may be required. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • DarunavirantiretroviralOrta

    …initial dosing and titration of quetiapine. e.g. perphenazine, risperidone, thioridazine ↑ antipsychotics A decrease in the dose of antipsychotics that are metabolized by CYP3A or CYP2D6 may be needed when co-administered with PREZISTA/ritonavir. β-Blockers : e.g. carvedilol, metoprolol, timolol ↑ beta-blockers Clinical monitoring of patients is recommended. (Darunavir etiketi, İlaç etkileşimleri)

  • Darunavir ve kobisistatantiretroviralOrta

    Initiation of quetiapine in patients taking PREZCOBIX or PREZCOBIX PED : Refer to the quetiapine prescribing information for initial dosing and titration of quetiapine. β-Blockers: e.g. carvedilol, metoprolol, timolol ↑ beta-blockers Clinical monitoring is recommended for co-administration with beta-blockers that are metabolized by CYP2D6. (Darunavir ve kobisistat etiketi, İlaç etkileşimleri)

  • Dekslansoprazolproton pompası inhibitörüOrta

    For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ] . (Dekslansoprazol etiketi, Uyarılar ve önlemler)

  • DeksmetilfenidatMSS uyarıcısıOrta

    • Antihypertensive Drugs: Monitor blood pressure. (Deksmetilfenidat etiketi, İlaç etkileşimleri)

  • Desipramintrisiklik antidepresanOrta

    Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with NORPRAMIN. (Desipramin etiketi, Uyarılar)

  • …Hyponatremia Concomitant administration of DESMODA with other drugs that may increase the risk of water intoxication with hyponatremia, (e.g., tricyclic antidepressants, selective serotonin re-uptake inhibitors, chlorpromazine, opiate analgesics, thiazide diuretics, NSAIDs, lamotrigine, sulfonylureas, particularly chlorpropamide, oxybutynin and carbamazepine). (Desmopressin etiketi, İlaç etkileşimleri)

  • Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk [see Use in Specific Populations (8.5) and Clinical Pharmacology (12.3) ] . (Desvenlafaksin etiketi, Uyarılar ve önlemler)

  • DietilpropionMSS uyarıcısıOrta

    The pressor effects of diethylpropion and those of other drugs may be additive when the drugs are used concomitantly; conversely, diethylpropion may interfere with antihypertensive drugs (i.e., guanethidine, a-methyldopa). (Dietilpropion etiketi, İlaç etkileşimleri)

  • DiflunisalNSAİİOrta

    Nonsteroidal anti-inflammatory drugs - In some patients, the administration of a nonsteroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium sparing, and thiazide diuretics. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Digoksindijital glikozidiOrta

    Bisoprolol fumarate and hydrochlorothiazide tablets should be used with caution when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently. (Bisoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

  • Dihidroergotaminergot alkaloidiOrta

    Beta Blockers Although the results of a clinical study did not indicate a safety problem associated with the administration of Dihydroergotamine Mesylate Injection, USP to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine. (Dihidroergotamin etiketi, İlaç etkileşimleri)

  • DiklofenakNSAİİOrta

    Nonsteroidal anti-inflammatory drugs - In some patients, the administration of a nonsteroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium sparing, and thiazide diuretics. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Nonsteroidal anti-inflammatory drugs - In some patients, the administration of a nonsteroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium sparing, and thiazide diuretics. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Dikloksasilinpenisilin antibiyotikOrta

    Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • Diltiazemkalsiyum kanal blokeriOrta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • DisopiramidantiaritmikOrta

    Bisoprolol fumarate and hydrochlorothiazide tablets should be used with caution when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently. (Bisoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

  • Doksazosinalfa blokerOrta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • DokserkalsiferolD vitamini analoğuOrta

    Risk may be increased when used concomitantly with high dose calcium preparations, thiazide diuretics, or vitamin D compounds. (Dokserkalsiferol etiketi, Uyarılar ve önlemler)

  • DötetrabenazinVMAT2 inhibitörüOrta

    Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored because the added beta-adrenergic blocking action of bisoprolol fumarate may produce excessive reduction of sympathetic activity. (Bisoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

  • DronedaronantiaritmikOrta

    Bisoprolol fumarate and hydrochlorothiazide tablets should be used with caution when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently. (Bisoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

  • Drospirenon ve etinilestradioloral kontraseptifOrta

    Medications that may increase serum potassium concentration include ACE inhibitors, angiotensin-II receptor antagonists, potassium-sparing diuretics, potassium supplementation, heparin, aldosterone antagonists, and NSAIDS. (Drospirenon ve etinilestradiol etiketi, Uyarılar ve önlemler)

  • DulaglutidGLP-1 reseptör agonistiOrta

    Antidiabetic drugs (oral agents and insulin) - dosage adjustment of the antidiabetic drug may be required. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • DuloksetinSNRIOrta

    The risk of BP decreases may be greater in patients taking concomitant medications that induce orthostatic hypotension (such as antihypertensives) or are potent CYP1A2 inhibitors [see Drug Interactions ( 7.1 )] and in patients taking duloxetine delayed-release capsules at doses above 60 mg daily. (Duloksetin etiketi, Uyarılar ve önlemler)

  • EksenatidGLP-1 reseptör agonistiOrta

    Antidiabetic drugs (oral agents and insulin) - dosage adjustment of the antidiabetic drug may be required. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • EluksadolinopioidOrta

    Alcohol, barbiturates, or narcotics - potentiation of orthostatic hypotension may occur. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Beta-Blockers: e.g., metoprolol timolol ↑ beta-blockers Clinical monitoring is recommended and a dosage decrease of the beta blocker may be necessary when these agents are coadministered with GENVOYA. (Elvitegravir, kobisistat, emtrisitabin ve tenofovir etiketi, İlaç etkileşimleri)

  • EmpagliflozinSGLT2 inhibitörüOrta

    Antidiabetic drugs (oral agents and insulin) - dosage adjustment of the antidiabetic drug may be required. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Empagliflozin ve metforminSGLT2 inhibitörüOrta

    Antidiabetic drugs (oral agents and insulin) - dosage adjustment of the antidiabetic drug may be required. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • EnalaprilACE inhibitörüOrta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • Enalapril ve hidroklorotiyazidACE inhibitörüOrta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Epoetin alfa etiketi, Uyarılar ve önlemler)

  • Epoprostenolprostaglandin analoğuOrta

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Epoprostenol etiketi, İlaç etkileşimleri)

  • Ergotamin ve kafeinergot alkaloidiOrta

    The beta-blocker Inderal (propranolol) has been reported to potentiate the vasoconstrictive action of ergotamine tartrate and caffeine tablets by blocking the vasodilating property of epinephrine. (Ergotamin ve kafein etiketi, İlaç etkileşimleri)

  • Esmololbeta blokerOrta

    Bisoprolol fumarate and hydrochlorothiazide tablets should be used with caution when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently. (Bisoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

  • Esomeprazolproton pompası inhibitörüOrta

    For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ] . (Esomeprazol etiketi, Uyarılar ve önlemler)

  • EssitalopramSSRIOrta

    Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (Essitalopram etiketi, Uyarılar ve önlemler)

  • EtodolakNSAİİOrta

    Nonsteroidal anti-inflammatory drugs - In some patients, the administration of a nonsteroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium sparing, and thiazide diuretics. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Felodipindihidropiridin kalsiyum kanal blokeriOrta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • FenelzinMAO inhibitörüOrta

    …hydrochloride desipramine hydrochloride imipramine hydrochloride doxepin carbamazepine cyclobenzaprine HCl amoxapine maprotiline HCl trimipramine maleate protriptyline HCl mirtazapine Phenelzine sulfate should be used with caution in combination with antihypertensive drugs, including thiazide diuretics and β-blockers, since exaggerated hypotensive effects may result. (Fenelzin etiketi, Uyarılar)

  • FenobarbitalbarbitüratOrta

    Alcohol, barbiturates, or narcotics - potentiation of orthostatic hypotension may occur. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Alcohol, barbiturates, or narcotics - potentiation of orthostatic hypotension may occur. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Fenoksibenzaminalfa blokerOrta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • FenoprofenNSAİİOrta

    Nonsteroidal anti-inflammatory drugs - In some patients, the administration of a nonsteroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium sparing, and thiazide diuretics. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • FentanilopioidOrta

    Alcohol, barbiturates, or narcotics - potentiation of orthostatic hypotension may occur. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Fentermin ve topiramatMSS uyarıcısıOrta

    Concomitant administration of hydrochlorothiazide alone with topiramate alone has been shown to increase the C max and AUC of topiramate by 27% and 29%, respectively. (Fentermin ve topiramat etiketi, İlaç etkileşimleri)

  • FludrokortizonkortikosteroidOrta

    Amphotericin B or potassium-depleting diuretics (benzothiadiazines and related drugs, ethacrynic acid and furosemide)—enhanced hypokalemia. (Fludrokortizon etiketi, İlaç etkileşimleri)

  • Flukonazolazol antifungalOrta

    Hydrochlorothiazide In a pharmacokinetic interaction study, coadministration of multiple-dose hydrochlorothiazide to healthy volunteers receiving fluconazole increased plasma concentrations of fluconazole by 40%. (Flukonazol etiketi, İlaç etkileşimleri)

  • FluoksetinSSRIOrta

    Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (Fluoksetin etiketi, Uyarılar ve önlemler)

  • FlurbiprofenNSAİİOrta

    Nonsteroidal anti-inflammatory drugs - In some patients, the administration of a nonsteroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium sparing, and thiazide diuretics. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Flutikazon ve salmeterolkortikosteroidOrta

    Diuretics: Use with caution. (Flutikazon ve salmeterol etiketi, İlaç etkileşimleri)

  • FluvoksaminSSRIOrta

    Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (Fluvoksamin etiketi, Uyarılar ve önlemler)

  • Formoterolbeta adrenerjik agonistOrta

    • Xanthine derivatives, steroids, diuretics, or non-potassium sparing diuretics may potentiate hypokalemia or ECG changes. (Formoterol etiketi, İlaç etkileşimleri)

  • FosinoprilACE inhibitörüOrta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • FoskarnetantiviralOrta

    When diuretics are indicated, thiazides are recommended over loop diuretics because the latter inhibit renal tubular secretion, and may impair elimination of FOSCAVIR, potentially leading to toxicity. (Foskarnet etiketi, İlaç etkileşimleri)

  • Furosemidkıvrım (loop) diüretiğiOrta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • GlibenklamidsülfonilüreOrta

    Beta-blockers may further increase the risk of severe hypoglycemia when used concurrently with sulfonylureas. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • Glibenklamid ve metforminsülfonilüreOrta

    Beta-blockers may further increase the risk of severe hypoglycemia when used concurrently with sulfonylureas. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • GlimepiridsülfonilüreOrta

    Beta-blockers may further increase the risk of severe hypoglycemia when used concurrently with sulfonylureas. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • GlipizidsülfonilüreOrta

    Beta-blockers may further increase the risk of severe hypoglycemia when used concurrently with sulfonylureas. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • Glipizid ve metforminsülfonilüreOrta

    Beta-blockers may further increase the risk of severe hypoglycemia when used concurrently with sulfonylureas. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (Glukagon etiketi, İlaç etkileşimleri)

  • Guanfasinalfa adrenerjik agonistOrta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • HaloperidolantipsikotikOrta

    Caution is advised when haloperidol decanoate is used in combination with drugs known to cause electrolyte imbalance (e.g., diuretics or corticosteroids) because hypokalemia, hypomagnesemia, and hypocalcemia are risk factors for QT prolongation. (Haloperidol etiketi, İlaç etkileşimleri)

  • HidralazinvazodilatörOrta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • Hidroklorotiyazidtiyazid diüretikOrta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • HidrokodonopioidOrta

    Alcohol, barbiturates, or narcotics - potentiation of orthostatic hypotension may occur. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Alcohol, barbiturates, or narcotics - potentiation of orthostatic hypotension may occur. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Alcohol, barbiturates, or narcotics - potentiation of orthostatic hypotension may occur. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Alcohol, barbiturates, or narcotics - potentiation of orthostatic hypotension may occur. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Alcohol, barbiturates, or narcotics - potentiation of orthostatic hypotension may occur. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • HidromorfonopioidOrta

    Alcohol, barbiturates, or narcotics - potentiation of orthostatic hypotension may occur. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • İbuprofenNSAİİOrta

    Nonsteroidal anti-inflammatory drugs - In some patients, the administration of a nonsteroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium sparing, and thiazide diuretics. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Nonsteroidal anti-inflammatory drugs - In some patients, the administration of a nonsteroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium sparing, and thiazide diuretics. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • İbutilidantiaritmikOrta

    Bisoprolol fumarate and hydrochlorothiazide tablets should be used with caution when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently. (Bisoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

  • İloperidonantipsikotikOrta

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive medications), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (İloperidon etiketi, Uyarılar ve önlemler)

  • İmipramintrisiklik antidepresanOrta

    Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with imipramine hydrochloride tablets. (İmipramin etiketi, Uyarılar)

  • İndapamidtiyazid diüretikOrta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • İndometazinNSAİİOrta

    Nonsteroidal anti-inflammatory drugs - In some patients, the administration of a nonsteroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium sparing, and thiazide diuretics. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • İnsülin aspartinsülinOrta

    Also, latent diabetes mellitus may become manifest and diabetic patients given thiazides may require adjustment of their insulin dose. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • İnsülin degludekinsülinOrta

    Also, latent diabetes mellitus may become manifest and diabetic patients given thiazides may require adjustment of their insulin dose. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • İnsülin detemirinsülinOrta

    Also, latent diabetes mellitus may become manifest and diabetic patients given thiazides may require adjustment of their insulin dose. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • İnsülin glarjininsülinOrta

    Also, latent diabetes mellitus may become manifest and diabetic patients given thiazides may require adjustment of their insulin dose. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • İnsülin lisproinsülinOrta

    Also, latent diabetes mellitus may become manifest and diabetic patients given thiazides may require adjustment of their insulin dose. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • İpratropium ve salbutamolantikolinerjikOrta

    Diuretics The electrocardiogram (ECG) changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by β-agonists, especially when the recommended dose of the β-agonist is exceeded. (İpratropium ve salbutamol etiketi, İlaç etkileşimleri)

  • İrbesartananjiyotensin II reseptör blokeri (ARB)Orta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • İrbesartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Orta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • İsradipindihidropiridin kalsiyum kanal blokeriOrta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • The risk of bradycardia increases with concomitant administration of drugs that slow heart rate (e.g., digoxin, amiodarone, beta-blockers). (İvabradin etiketi, İlaç etkileşimleri)

  • İzoflurangenel anestezikOrta

    Concomitant Use with Beta Blockers Concomitant use of beta blockers may exaggerate the cardiovascular effects of inhalational anesthetics, including hypotension and negative inotropic effects. (İzofluran etiketi, İlaç etkileşimleri)

  • Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • KalsitriolD vitamini analoğuOrta

    Thiazides Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine. (Kalsitriol etiketi, İlaç etkileşimleri)

  • Drugs That Increase the Risk of Hypercalcemia Increase frequency of monitoring of calcium concentrations in patients taking concomitant Calcium Chloride Injection and other drugs that increase the risk of hypercalcemia (e.g., calcipotriene, estrogen, lithium, parathyroid hormone, teriparatide, thiazide diuretics, Vitamin A, and Vitamin D). (Kalsiyum klorür etiketi, İlaç etkileşimleri)

  • KanagliflozinSGLT2 inhibitörüOrta

    Antidiabetic drugs (oral agents and insulin) - dosage adjustment of the antidiabetic drug may be required. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Kandesartananjiyotensin II reseptör blokeri (ARB)Orta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • Kandesartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Orta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • KaptoprilACE inhibitörüOrta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • KarbamazepinantikonvülsanOrta

    Elderly patients and patients treated with diuretics are at greater risk of developing hyponatremia. (Karbamazepin etiketi, Uyarılar ve önlemler)

  • Symptomatic postural hypotension has occurred when carbidopa, given with levodopa or carbidopa-levodopa combination products, was added to the treatment of a patient receiving antihypertensive drugs. (Karbidopa etiketi, İlaç etkileşimleri)

  • Karbidopa ve levodopadopaminerjik ilaçOrta

    Antihypertensive drugs: May cause symptomatic postural hypotension. (Karbidopa ve levodopa etiketi, İlaç etkileşimleri)

  • Karbidopa, levodopa ve entakapondopaminerjik ilaçOrta

    Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (Karbidopa, levodopa ve entakapon etiketi, İlaç etkileşimleri)

  • KariprazinantipsikotikOrta

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive medications), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (Kariprazin etiketi, Uyarılar ve önlemler)

  • Karisoprodolkas gevşeticiOrta

    Skeletal muscle relaxants, nondepolarizing (e.g., tubocurarine) - possible increased responsiveness to the muscle relaxant. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Karvedilolbeta blokerOrta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • KetiapinantipsikotikOrta

    Quetiapine should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities), cerebrovascular disease, or conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (Ketiapin etiketi, Uyarılar ve önlemler)

  • Ketokonazolazol antifungalOrta

    Antivirals indinavir, maraviroc, saquinavir Beta Blockers nadolol Calcium Channel Blockers felodipine, nisoldipine other dihydropyridines, verapamil Calcium channel blockers can have a negative inotropic effect which may be additive to those of ketoconazole. (Ketokonazol etiketi, İlaç etkileşimleri)

  • KetoprofenNSAİİOrta

    Nonsteroidal anti-inflammatory drugs - In some patients, the administration of a nonsteroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium sparing, and thiazide diuretics. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • KetorolakNSAİİOrta

    Nonsteroidal anti-inflammatory drugs - In some patients, the administration of a nonsteroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium sparing, and thiazide diuretics. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Kinapril ve hidroklorotiyazidACE inhibitörüOrta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • KinidinantiaritmikOrta

    Bisoprolol fumarate and hydrochlorothiazide tablets should be used with caution when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently. (Bisoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

  • KlofarabinantimetabolitOrta

    Consider use of diuretics and/or albumin. (Klofarabin etiketi, Uyarılar ve önlemler)

  • Klonidinalfa adrenerjik agonistOrta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • Klorotiyazidtiyazid diüretikOrta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • KlorpromazinantipsikotikOrta

    Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (Klorpromazin etiketi, Önlemler)

  • Klortalidontiyazid diüretikOrta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • Klorzoksazonkas gevşeticiOrta

    Skeletal muscle relaxants, nondepolarizing (e.g., tubocurarine) - possible increased responsiveness to the muscle relaxant. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • KodeinopioidOrta

    Alcohol, barbiturates, or narcotics - potentiation of orthostatic hypotension may occur. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Kolestipolsafra asidi bağlayıcıOrta

    Single doses of cholestyramine and colestipol resins bind the hydrochlorothiazide and reduce its absorption in the gastrointestinal tract by up to 85 percent and 43 percent, respectively. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Kolestiraminsafra asidi bağlayıcıOrta

    Single doses of cholestyramine and colestipol resins bind the hydrochlorothiazide and reduce its absorption in the gastrointestinal tract by up to 85 percent and 43 percent, respectively. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Labetalolbeta blokerOrta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • LakozamidantikonvülsanOrta

    VIMPAT should also be used with caution in patients on concomitant medications that affect cardiac conduction, including sodium channel blockers, beta-blockers, calcium channel blockers, potassium channel blockers, and medications that prolong the PR interval [see Drug Interactions (7.2) ] . (Lakozamid etiketi, Uyarılar ve önlemler)

  • Bradycardia-Inducing Drugs (e.g., beta-blockers) : Lanreotide Injection may decrease heart rate. (Lanreotid etiketi, İlaç etkileşimleri)

  • Lansoprazolproton pompası inhibitörüOrta

    For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ] . (Lansoprazol etiketi, Uyarılar ve önlemler)

  • Patients also taking beta blockers, or those with underlying cardiac comorbidities and/or advanced liver disease, may be at increased risk for symptomatic bradycardia with coadministration of amiodarone. (Ledipasvir ve sofosbuvir etiketi, Uyarılar ve önlemler)

  • Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (Levomilnasipran etiketi, Uyarılar ve önlemler)

  • LevorfanolopioidOrta

    Alcohol, barbiturates, or narcotics - potentiation of orthostatic hypotension may occur. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Levosalbutamolbeta adrenerjik agonistOrta

    In this setting, cardioselective beta-blockers should be considered, although they should be administered with caution. (Levosalbutamol etiketi, İlaç etkileşimleri)

  • Levotiroksintiroid hormonuOrta

    Laboratory Test Interactions Based on reports involving thiazides, bisoprolol fumarate and hydrochlorothiazide tablets may decrease serum levels of protein-bound iodine without signs of thyroid disturbance. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Levotiroksin ve liyotironintiroid hormonuOrta

    Laboratory Test Interactions Based on reports involving thiazides, bisoprolol fumarate and hydrochlorothiazide tablets may decrease serum levels of protein-bound iodine without signs of thyroid disturbance. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Lidokainlokal anestezikOrta

    Bisoprolol fumarate and hydrochlorothiazide tablets should be used with caution when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently. (Bisoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

  • Lidokain ve adrenalinlokal anestezikOrta

    Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reactions. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Lidokain ve prilokainlokal anestezikOrta

    Bisoprolol fumarate and hydrochlorothiazide tablets should be used with caution when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently. (Bisoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

  • LinagliptinDPP-4 inhibitörüOrta

    Antidiabetic drugs (oral agents and insulin) - dosage adjustment of the antidiabetic drug may be required. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Linagliptin ve metforminDPP-4 inhibitörüOrta

    Antidiabetic drugs (oral agents and insulin) - dosage adjustment of the antidiabetic drug may be required. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • LinezolidantibiyotikOrta

    Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (Linezolid etiketi, Uyarılar ve önlemler)

  • LiraglutidGLP-1 reseptör agonistiOrta

    Antidiabetic drugs (oral agents and insulin) - dosage adjustment of the antidiabetic drug may be required. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • LisinoprilACE inhibitörüOrta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • Lityumserotonerjik ilaçOrta

    Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Liyotironintiroid hormonuOrta

    Laboratory Test Interactions Based on reports involving thiazides, bisoprolol fumarate and hydrochlorothiazide tablets may decrease serum levels of protein-bound iodine without signs of thyroid disturbance. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Lofeksidinalfa adrenerjik agonistOrta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • Lopinavir ve ritonavirantiretroviralOrta

    The impact on the PR interval of co-administration of KALETRA with other drugs that prolong the PR interval (including calcium channel blockers, beta-adrenergic blockers, digoxin and atazanavir) has not been evaluated. (Lopinavir ve ritonavir etiketi, Uyarılar ve önlemler)

  • Losartananjiyotensin II reseptör blokeri (ARB)Orta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • Losartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Orta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • LumateperonantipsikotikOrta

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (Lumateperon etiketi, Uyarılar ve önlemler)

  • LurasidonantipsikotikOrta

    Patients at increased risk of these adverse reactions or at increased risk of developing complications from hypotension include those with dehydration, hypovolemia, treatment with antihypertensive medication, history of cardiovascular disease (e.g., heart failure, myocardial infarction, ischemia, or conduction abnormalities), history of cerebrovascular disease,… (Lurasidon etiketi, Uyarılar ve önlemler)

  • Mefenamik asitNSAİİOrta

    Nonsteroidal anti-inflammatory drugs - In some patients, the administration of a nonsteroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium sparing, and thiazide diuretics. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • MeflokinantimalaryalOrta

    There is one report of cardiopulmonary arrest, with full recovery, in a patient who was taking a beta blocker (propranolol) (see PRECAUTIONS, Cardiac Effects ). (Meflokin etiketi, İlaç etkileşimleri)

  • MekamilaminantihipertansifOrta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • MeksiletinantiaritmikOrta

    Bisoprolol fumarate and hydrochlorothiazide tablets should be used with caution when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently. (Bisoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

  • MeloksikamNSAİİOrta

    Nonsteroidal anti-inflammatory drugs - In some patients, the administration of a nonsteroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium sparing, and thiazide diuretics. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • MetadonopioidOrta

    Alcohol, barbiturates, or narcotics - potentiation of orthostatic hypotension may occur. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Metaksalonkas gevşeticiOrta

    Skeletal muscle relaxants, nondepolarizing (e.g., tubocurarine) - possible increased responsiveness to the muscle relaxant. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • MetforminbiguanidOrta

    Antidiabetic drugs (oral agents and insulin) - dosage adjustment of the antidiabetic drug may be required. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • MetildopaantihipertansifOrta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • Metilergometrinergot alkaloidiOrta

    Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (Metilergometrin etiketi, İlaç etkileşimleri)

  • MetilfenidatMSS uyarıcısıOrta

    Antihypertensive Drugs: Monitor blood pressure. (Metilfenidat etiketi, İlaç etkileşimleri)

  • Metimazolantitiroid ilaçOrta

    Laboratory Test Interactions Based on reports involving thiazides, bisoprolol fumarate and hydrochlorothiazide tablets may decrease serum levels of protein-bound iodine without signs of thyroid disturbance. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • MetoheksitalbarbitüratOrta

    Alcohol, barbiturates, or narcotics - potentiation of orthostatic hypotension may occur. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Metokarbamolkas gevşeticiOrta

    Skeletal muscle relaxants, nondepolarizing (e.g., tubocurarine) - possible increased responsiveness to the muscle relaxant. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Metoprololbeta blokerOrta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • MiglitolantidiyabetikOrta

    Antidiabetic drugs (oral agents and insulin) - dosage adjustment of the antidiabetic drug may be required. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • MilnasipranSNRIOrta

    Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (Milnasipran etiketi, Uyarılar ve önlemler)

  • MirtazapinantidepresanOrta

    Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia [see Use in Specific Populations (8.5) ] . (Mirtazapin etiketi, Uyarılar ve önlemler)

  • ModafinilMSS uyarıcısıOrta

    However, a retrospective analysis of the use of antihypertensive medication in these studies showed that a greater proportion of patients on PROVIGIL required new or increased use of antihypertensive medications (2.4%) compared to patients on placebo (0.7%). (Modafinil etiketi, Uyarılar ve önlemler)

  • MoeksiprilACE inhibitörüOrta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • MorfinopioidOrta

    Alcohol, barbiturates, or narcotics - potentiation of orthostatic hypotension may occur. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Patients receiving concomitant negative chronotropic drugs (e.g., beta blockers) may be more at risk for hypotension in case of hypersensitivity reaction. (Motiksafortid etiketi, Uyarılar ve önlemler)

  • NabumetonNSAİİOrta

    Nonsteroidal anti-inflammatory drugs - In some patients, the administration of a nonsteroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium sparing, and thiazide diuretics. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Nadololbeta blokerOrta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • Nafsilinpenisilin antibiyotikOrta

    Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • NalbufinopioidOrta

    Alcohol, barbiturates, or narcotics - potentiation of orthostatic hypotension may occur. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Naltrekson ve bupropionopioid antagonistiOrta

    Drugs Metabolized by CYP2D6: Bupropion inhibits CYP2D6 and can increase concentrations of antidepressants, (e.g., selective serotonin reuptake inhibitors and many tricyclics), antipsychotics (e.g., haloperidol, risperidone and thioridazine), beta-blockers (e.g., metoprolol) and Type 1C antiarrhythmics (e.g., propafenone and flecainide). (Naltrekson ve bupropion etiketi, İlaç etkileşimleri)

  • NaproksenNSAİİOrta

    Nonsteroidal anti-inflammatory drugs - In some patients, the administration of a nonsteroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium sparing, and thiazide diuretics. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Nonsteroidal anti-inflammatory drugs - In some patients, the administration of a nonsteroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium sparing, and thiazide diuretics. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • NateglinidmeglitinidOrta

    Antidiabetic drugs (oral agents and insulin) - dosage adjustment of the antidiabetic drug may be required. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • NiasinOrta

    Antihypertensive Therapy Niacin may potentiate the effects of ganglionic blocking agents and vasoactive drugs resulting in postural hypotension. (Niasin etiketi, İlaç etkileşimleri)

  • Nifedipindihidropiridin kalsiyum kanal blokeriOrta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • Nikardipindihidropiridin kalsiyum kanal blokeriOrta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • Nimodipindihidropiridin kalsiyum kanal blokeriOrta

    Bisoprolol fumarate and hydrochlorothiazide tablets should be used with caution when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently. (Bisoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

  • Nisoldipindihidropiridin kalsiyum kanal blokeriOrta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • NitrogliserinnitratOrta

    Antihypertensives: Possible additive hypotensive effects. (Nitrogliserin etiketi, İlaç etkileşimleri)

  • NitroprussidvazodilatörOrta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • OksaprozinNSAİİOrta

    Nonsteroidal anti-inflammatory drugs - In some patients, the administration of a nonsteroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium sparing, and thiazide diuretics. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Oksasilinpenisilin antibiyotikOrta

    Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • OksikodonopioidOrta

    Alcohol, barbiturates, or narcotics - potentiation of orthostatic hypotension may occur. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Alcohol, barbiturates, or narcotics - potentiation of orthostatic hypotension may occur. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • OksimetazolindekonjestanOrta

    Caution in using drugs such as beta-blockers, anti-hypertensives, and/or cardiac glycosides is advised. (Oksimetazolin etiketi, İlaç etkileşimleri)

  • OksimorfonopioidOrta

    Alcohol, barbiturates, or narcotics - potentiation of orthostatic hypotension may occur. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (Oktreotid etiketi, Uyarılar ve önlemler)

  • OlanzapinantipsikotikOrta

    …of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, and conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications) where the occurrence of syncope, or hypotension and/or bradycardia might put the patient at increased medical risk. (Olanzapin etiketi, Uyarılar ve önlemler)

  • Olanzapin ve fluoksetinantipsikotikOrta

    …and fluoxetine capsules should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, or conditions that would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (Olanzapin ve fluoksetin etiketi, Uyarılar ve önlemler)

  • OliseridinopioidOrta

    Alcohol, barbiturates, or narcotics - potentiation of orthostatic hypotension may occur. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Olmesartananjiyotensin II reseptör blokeri (ARB)Orta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • Olmesartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Orta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • Olmesartan, amlodipin ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Orta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • Omeprazolproton pompası inhibitörüOrta

    For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions ( 6.2 )] . (Omeprazol etiketi, Uyarılar ve önlemler)

  • Omeprazol ve sodyum bikarbonatproton pompası inhibitörüOrta

    For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions ( 6.2 )] . (Omeprazol ve sodyum bikarbonat etiketi, Uyarılar ve önlemler)

  • Orfenadrinkas gevşeticiOrta

    Skeletal muscle relaxants, nondepolarizing (e.g., tubocurarine) - possible increased responsiveness to the muscle relaxant. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Skeletal muscle relaxants, nondepolarizing (e.g., tubocurarine) - possible increased responsiveness to the muscle relaxant. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • PaliperidonantipsikotikOrta

    Use ERZOFRI with caution in patients with known cardiovascular disease (e.g., heart failure, history of myocardial infarction or ischemia, conduction abnormalities), cerebrovascular disease, or conditions that predispose the patient to hypotension (e.g., dehydration, hypovolemia, and treatment with antihypertensive medications). (Paliperidon etiketi, Uyarılar ve önlemler)

  • Pantoprazolproton pompası inhibitörüOrta

    For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ]. (Pantoprazol etiketi, Uyarılar ve önlemler)

  • Nonsteroidal anti-inflammatory drugs - In some patients, the administration of a nonsteroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium sparing, and thiazide diuretics. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Alcohol, barbiturates, or narcotics - potentiation of orthostatic hypotension may occur. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • ParikalsitolD vitamini analoğuOrta

    The risk may be increased when Paricalcitol Injection is used concomitantly with high dose calcium preparations, thiazide diuretics, or vitamin D compounds. (Parikalsitol etiketi, Uyarılar ve önlemler)

  • ParoksetinSSRIOrta

    Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SNRIs and SSRIs. [see Use in Specific Populations ( 8.5 )]. (Paroksetin etiketi, Uyarılar ve önlemler)

  • Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (Pasireotid etiketi, Uyarılar ve önlemler)

  • Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib etiketi, Uyarılar ve önlemler)

  • Penisilin Gpenisilin antibiyotikOrta

    Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • Penisilin Vpenisilin antibiyotikOrta

    Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • Alcohol, barbiturates, or narcotics - potentiation of orthostatic hypotension may occur. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • PentoksifilinmetilksantinOrta

    Small decreases in blood pressure have been observed in some patients treated with pentoxifylline extended-release tablets; periodic systemic blood pressure monitoring is recommended for patients receiving concomitant antihypertensive therapy. (Pentoksifilin etiketi, İlaç etkileşimleri)

  • PerindoprilACE inhibitörüOrta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • PetidinopioidOrta

    Alcohol, barbiturates, or narcotics - potentiation of orthostatic hypotension may occur. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Pilokarpinkolinerjik agonistOrta

    Drug Interactions Pilocarpine should be administered with caution to patients taking beta-adrenergic antagonists because of the possibility of conduction disturbances. (Pilokarpin etiketi, İlaç etkileşimleri)

  • Pindololbeta blokerOrta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • PioglitazontiyazolidindionOrta

    Antidiabetic drugs (oral agents and insulin) - dosage adjustment of the antidiabetic drug may be required. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Pioglitazon ve glimepiridtiyazolidindionOrta

    Beta-blockers may further increase the risk of severe hypoglycemia when used concurrently with sulfonylureas. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • Pioglitazon ve metformintiyazolidindionOrta

    Antidiabetic drugs (oral agents and insulin) - dosage adjustment of the antidiabetic drug may be required. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Piperasilin ve tazobaktampenisilin antibiyotikOrta

    Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • Piridostigminkolinesteraz inhibitörüOrta

    Use with caution in persons with increased risk of anticholinergic reactions, such as persons with bronchial asthma, chronic obstructive pulmonary disease, bradycardia, cardiac arrhythmias, beta blocker treatment (increased risk of anticholinergic reactions). (Piridostigmin etiketi, Uyarılar ve önlemler)

  • PiroksikamNSAİİOrta

    Nonsteroidal anti-inflammatory drugs - In some patients, the administration of a nonsteroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium sparing, and thiazide diuretics. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • PonesimodimmünosüpresanOrta

    Experience with PONVORY is limited in patients receiving concurrent therapy with drugs that decrease heart rate (e.g., beta-blockers, non-dihydropyridine calcium channel blockers - diltiazem and verapamil, and other drugs that may decrease heart rate such as digoxin). (Ponesimod etiketi, Uyarılar ve önlemler)

  • Concurrent use with potassium-containing medications, potassium-sparing diuretics and angiotensin-converting enzyme inhibitors (ACE inhibitors) may result in hyperkalemia and cardiac arrhythmias or cardiac arrest. (Potasyum iyodür etiketi, İlaç etkileşimleri)

  • Prazosinalfa blokerOrta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • Prilokain ve adrenalinlokal anestezikOrta

    Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reactions. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • PrimidonantikonvülsanOrta

    Alcohol, barbiturates, or narcotics - potentiation of orthostatic hypotension may occur. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • ProkainamidantiaritmikOrta

    Bisoprolol fumarate and hydrochlorothiazide tablets should be used with caution when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently. (Bisoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

  • ProklorperazinantipsikotikOrta

    Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (Proklorperazin etiketi, Önlemler)

  • Alcohol, barbiturates, or narcotics - potentiation of orthostatic hypotension may occur. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • PropafenonantiaritmikOrta

    Bisoprolol fumarate and hydrochlorothiazide tablets should be used with caution when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently. (Bisoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

  • Propiltiourasilantitiroid ilaçOrta

    Laboratory Test Interactions Based on reports involving thiazides, bisoprolol fumarate and hydrochlorothiazide tablets may decrease serum levels of protein-bound iodine without signs of thyroid disturbance. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Propranololbeta blokerOrta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • Rabeprazolproton pompası inhibitörüOrta

    For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ]. (Rabeprazol etiketi, Uyarılar ve önlemler)

  • RamiprilACE inhibitörüOrta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • Also, latent diabetes mellitus may become manifest and diabetic patients given thiazides may require adjustment of their insulin dose. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • RemifentanilopioidOrta

    Alcohol, barbiturates, or narcotics - potentiation of orthostatic hypotension may occur. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • RifampisinantibiyotikOrta

    Bisoprolol Fumarate Concurrent use of rifampin increases the metabolic clearance of bisoprolol fumarate, shortening its elimination half-life. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • RifapentinantibiyotikOrta

    …Anticonvulsants Phenytoin Antimalarials Quinine Azole Antifungals Fluconazole, itraconazole, ketoconazole Antipsychotics Haloperidol Barbiturates Phenobarbital Benzodiazepines Diazepam Beta-Blockers Propranolol Calcium Channel Blockers Diltiazem, nifedipine, verapamil Cardiac Glycoside Preparations Digoxin Corticosteroids Prednisone Fibrates Clofibrate Oral Hypoglycemics… (Rifapentin etiketi, İlaç etkileşimleri)

  • RiosiguatvazodilatörOrta

    Consider the potential for symptomatic hypotension or ischemia in patients with hypovolemia, severe left ventricular outflow obstruction, resting hypotension, autonomic dysfunction, or concomitant treatment with antihypertensives or strong CYP and P-gp/BCRP inhibitors [see Drug Interactions (7.2) and Clinical Pharmacology (12.3) ] . (Riosiguat etiketi, Uyarılar ve önlemler)

  • RisperidonantipsikotikOrta

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (Risperidon etiketi, Uyarılar ve önlemler)

  • RitonavirantiretroviralOrta

    The impact on the PR interval of co-administration of ritonavir with other drugs that prolong the PR interval (including calcium channel blockers, beta-adrenergic blockers, digoxin and atazanavir) has not been evaluated. (Ritonavir etiketi, Uyarılar ve önlemler)

  • Ropivakainlokal anestezikOrta

    Patients on beta-blockers may not manifest changes in heart rate, but blood pressure monitoring can detect a rise in systolic blood pressure. (Ropivakain etiketi, Uyarılar ve önlemler)

  • SaksagliptinDPP-4 inhibitörüOrta

    Antidiabetic drugs (oral agents and insulin) - dosage adjustment of the antidiabetic drug may be required. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Saksagliptin ve metforminDPP-4 inhibitörüOrta

    Antidiabetic drugs (oral agents and insulin) - dosage adjustment of the antidiabetic drug may be required. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Sakubitril ve valsartananjiyotensin II reseptör blokeri (ARB)Orta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • Salbutamolbeta adrenerjik agonistOrta

    Beta-blockers: Use with caution. (Salbutamol etiketi, İlaç etkileşimleri)

  • Salmeterolbeta adrenerjik agonistOrta

    • Beta-blockers: Use with caution. (Salmeterol etiketi, İlaç etkileşimleri)

  • SalsalatNSAİİOrta

    Nonsteroidal anti-inflammatory drugs - In some patients, the administration of a nonsteroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium sparing, and thiazide diuretics. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • SefepimsefalosporinOrta

    Diuretics: Nephrotoxicity has been reported with concomitant administration of cephalosporins with potent diuretics such as furosemide. (Sefepim etiketi, İlaç etkileşimleri)

  • SeftazidimsefalosporinOrta

    Drug Interactions Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibacterial drugs or potent diuretics such as furosemide. (Seftazidim etiketi, İlaç etkileşimleri)

  • SelekoksibNSAİİOrta

    Nonsteroidal anti-inflammatory drugs - In some patients, the administration of a nonsteroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium sparing, and thiazide diuretics. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • SemaglutidGLP-1 reseptör agonistiOrta

    Antidiabetic drugs (oral agents and insulin) - dosage adjustment of the antidiabetic drug may be required. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • SertralinSSRIOrta

    Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs [see Use in Specific Populations ( 8.5 )] . (Sertralin etiketi, Uyarılar ve önlemler)

  • Sevimelinkolinerjik agonistOrta

    DRUG INTERACTIONS Cevimeline should be administered with caution to patients taking beta adrenergic antagonists, because of the possibility of conduction disturbances. (Sevimelin etiketi, İlaç etkileşimleri)

  • Siklobenzaprinkas gevşeticiOrta

    Skeletal muscle relaxants, nondepolarizing (e.g., tubocurarine) - possible increased responsiveness to the muscle relaxant. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • SiklofosfamidimmünosüpresanOrta

    …inhibitors: ACE inhibitors can cause leukopenia. ● Natalizumab ● Paclitaxel: Increased hematotoxicity has been reported when cyclophosphamide was administered after paclitaxel infusion. ● Thiazide diuretics ● Zidovudine Increased cardiotoxicity ● Anthracyclines ● Cytarabine ● Pentostatin ● Radiation therapy of the cardiac region ● Trastuzumab Increased pulmonary toxicity… (Siklofosfamid etiketi, İlaç etkileşimleri)

  • SildenafilPDE5 inhibitörüOrta

    Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (Sildenafil etiketi, Uyarılar ve önlemler)

  • Silodosinalfa blokerOrta

    However, patients in the Phase 3 clinical studies taking concomitant antihypertensive medications with silodosin capsules did not experience a significant increase in the incidence of syncope, dizziness, or orthostasis. (Silodosin etiketi, Uyarılar ve önlemler)

  • SitagliptinDPP-4 inhibitörüOrta

    Antidiabetic drugs (oral agents and insulin) - dosage adjustment of the antidiabetic drug may be required. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Sitagliptin ve metforminDPP-4 inhibitörüOrta

    Antidiabetic drugs (oral agents and insulin) - dosage adjustment of the antidiabetic drug may be required. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • SitalopramSSRIOrta

    Elderly patients, patients taking diuretics, and those who are volume depleted may be at greater risk for developing hyponatremia with SSRIs [see Use in Specific Populations ( 8.5 )] . (Sitalopram etiketi, Uyarılar ve önlemler)

  • Increase the dose of diuretics as needed [see Adverse Reactions (6) ] . (Sodyum zirkonyum siklosilikat etiketi, Uyarılar ve önlemler)

  • Patients also taking beta blockers, or those with underlying cardiac comorbidities and/or advanced liver disease may be at increased risk for symptomatic bradycardia with coadministration of amiodarone. (Sofosbuvir ve velpatasvir etiketi, Uyarılar ve önlemler)

  • Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Sotalolbeta blokerOrta

    Bisoprolol fumarate and hydrochlorothiazide tablets should be used with caution when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently. (Bisoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

  • Spironolaktonaldosteron antagonistiOrta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • Spironolakton ve hidroklorotiyazidaldosteron antagonistiOrta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • SulindakNSAİİOrta

    Nonsteroidal anti-inflammatory drugs - In some patients, the administration of a nonsteroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium sparing, and thiazide diuretics. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Nonsteroidal anti-inflammatory drugs - In some patients, the administration of a nonsteroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium sparing, and thiazide diuretics. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib etiketi, Uyarılar ve önlemler)

  • Süksinilkolinnöromüsküler blokerOrta

    Prolonged Neuromuscular Block in Patients with Hypokalemia or Hypocalcemia Neuromuscular blockade may be prolonged in patients with hypokalemia (e.g., after severe vomiting, diarrhea, digitalisation and diuretic therapy) or hypocalcemia (e.g., after massive transfusions). (Süksinilkolin etiketi, Uyarılar ve önlemler)

  • TakrolimusimmünosüpresanOrta

    • Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (Takrolimus etiketi, Uyarılar ve önlemler)

  • TapentadolopioidOrta

    Alcohol, barbiturates, or narcotics - potentiation of orthostatic hypotension may occur. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Telmisartananjiyotensin II reseptör blokeri (ARB)Orta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • Telmisartan ve amlodipinanjiyotensin II reseptör blokeri (ARB)Orta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • Telmisartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Orta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • Terazosinalfa blokerOrta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • Terbutalinbeta adrenerjik agonistOrta

    In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution. (Terbutalin etiketi, Önlemler)

  • Teriparatidtiroid hormonuOrta

    Laboratory Test Interactions Based on reports involving thiazides, bisoprolol fumarate and hydrochlorothiazide tablets may decrease serum levels of protein-bound iodine without signs of thyroid disturbance. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • TestosteronandrojenOrta

    In patients with hypertension on antihypertensive therapy, TLANDO increased the mean systolic/diastolic BP by 4.8/1.6 mm Hg from baseline. [see Adverse Reactions ( 6.1 )] . (Testosteron etiketi, Uyarılar ve önlemler)

  • TetrabenazinVMAT2 inhibitörüOrta

    Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored because the added beta-adrenergic blocking action of bisoprolol fumarate may produce excessive reduction of sympathetic activity. (Bisoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

  • TirzepatidGLP-1 reseptör agonistiOrta

    Also, latent diabetes mellitus may become manifest and diabetic patients given thiazides may require adjustment of their insulin dose. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • Tizanidinkas gevşeticiOrta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • TobramisinaminoglikozidOrta

    Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (Tobramisin etiketi, İlaç etkileşimleri)

  • TolmetinNSAİİOrta

    Nonsteroidal anti-inflammatory drugs - In some patients, the administration of a nonsteroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium sparing, and thiazide diuretics. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Co-administration of diuretics also increases the risk of too rapid correction of serum sodium and such patients should undergo close monitoring of serum sodium. (Tolvaptan etiketi, Uyarılar ve önlemler)

  • TopiramatantikonvülsanOrta

    Hydrochlorothiazide (HCTZ) Topiramate C max and AUC increased when HCTZ was added to immediate-release topiramate. (Topiramat etiketi, İlaç etkileşimleri)

  • Torasemidkıvrım (loop) diüretiğiOrta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • Toremifenselektif östrojen reseptör modülatörüOrta

    Drugs that decrease renal calcium excretion, e.g., thiazide diuretics, may increase the risk of hypercalcemia in patients receiving FARESTON. (Toremifen etiketi, İlaç etkileşimleri)

  • TramadolopioidOrta

    Alcohol, barbiturates, or narcotics - potentiation of orthostatic hypotension may occur. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Alcohol, barbiturates, or narcotics - potentiation of orthostatic hypotension may occur. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • TrandolaprilACE inhibitörüOrta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • TrazodonantidepresanOrta

    Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (Trazodon etiketi, Uyarılar ve önlemler)

  • Triamterenpotasyum tutucu diüretikOrta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • Triamteren ve hidroklorotiyazidpotasyum tutucu diüretikOrta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • TrifluoperazinantipsikotikOrta

    Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (Trifluoperazin etiketi, Önlemler)

  • Umeklidinyum ve vilanterolantikolinerjikOrta

    • Beta-blockers: Use with caution. (Umeklidinyum ve vilanterol etiketi, İlaç etkileşimleri)

  • ValbenazinVMAT2 inhibitörüOrta

    Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored because the added beta-adrenergic blocking action of bisoprolol fumarate may produce excessive reduction of sympathetic activity. (Bisoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

  • Valsartananjiyotensin II reseptör blokeri (ARB)Orta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • Valsartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Orta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • VardenafilPDE5 inhibitörüOrta

    Vardenafil hydrochloride tablets can potentiate the hypotensive effects of nitrates, alpha- blockers, and antihypertensives. (Vardenafil etiketi, İlaç etkileşimleri)

  • VarfarinantikoagülanOrta

    There was no effect of bisoprolol fumarate on prothrombin times in patients on stable doses of warfarin. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • VenlafaksinSNRIOrta

    Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (Venlafaksin etiketi, Uyarılar ve önlemler)

  • Verapamilkalsiyum kanal blokeriOrta

    Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • VilazodonSSRIOrta

    Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs and SNRIs [see Use in Specific Populations ( 8.5 )] . (Vilazodon etiketi, Uyarılar ve önlemler)

  • VortioksetinantidepresanOrta

    Also, patients taking diuretics or who are otherwise volume-depleted can be at greater risk. (Vortioksetin etiketi, Uyarılar ve önlemler)

  • ZileutonCYP1A2 inhibitörüOrta

    Zileuton increases propranolol levels and beta-blocker activity. (Zileuton etiketi, İlaç etkileşimleri)

  • ZiprasidonantipsikotikOrta

    Hypokalemia may result from diuretic therapy, diarrhea, and other causes. (Ziprasidon etiketi, Uyarılar ve önlemler)

  • Zoledronik asitbifosfonatOrta

    Elderly patients and those receiving diuretic therapy are at increased risk of acute renal failure. (Zoledronik asit etiketi, Uyarılar ve önlemler)

Minör değinmeler (57)

  • AklidinyumantikolinerjikMinör

    A beta 2 agonist (bronchodilator) should be made available. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • AmantadinantikolinerjikMinör

    Coadministration of 1 Dyazide (triamterene/hydrochlorothiazide) resulted in a higher plasma amantadine hydrochloride concentration in a 61-year old man receiving amantadine hydrochloride 100 mg TID for Parkinson's disease. (Amantadin etiketi, İlaç etkileşimleri)

  • Patients required intervention with a diuretic, fluid management, or, in some cases, hospitalization for decompensating heart failure. (Ambrisentan etiketi, Uyarılar ve önlemler)

  • AminofilinmetilksantinMinör

    A beta 2 agonist (bronchodilator) should be made available. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • Azelastin ve flutikazonantihistaminikMinör

    Corticosteroids, ACTH - Intensified electrolyte depletion, particularly hypokalemia. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • BeklometazonkortikosteroidMinör

    Corticosteroids, ACTH - Intensified electrolyte depletion, particularly hypokalemia. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • BetametazonkortikosteroidMinör

    Corticosteroids, ACTH - Intensified electrolyte depletion, particularly hypokalemia. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • BosentanCYP3A4 indükleyicisiMinör

    Patients required intervention with a diuretic, fluid management, or hospitalization for decompensating heart failure. (Bosentan etiketi, Uyarılar ve önlemler)

  • BudesonidkortikosteroidMinör

    Corticosteroids, ACTH - Intensified electrolyte depletion, particularly hypokalemia. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • ÇinkoVitamin ve mineralMinör

    Tiyazid diüretikler uzun süreli kullanımda idrarla çinko kaybını artırır. (NIH Office of Dietary Supplements, Zinc)

  • DasatinibMinör

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib etiketi, Uyarılar ve önlemler)

  • DeflazakortkortikosteroidMinör

    Corticosteroids, ACTH - Intensified electrolyte depletion, particularly hypokalemia. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • DeksametazonkortikosteroidMinör

    Corticosteroids, ACTH - Intensified electrolyte depletion, particularly hypokalemia. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • DekstroamfetaminMSS uyarıcısıMinör

    Examples of alkalinizing agents include gastrointestinal alkalinizing agents (e.g., sodium bicarbonate) and urinary alkalinizing agents (e.g. acetazolamide, some thiazides). (Dekstroamfetamin etiketi, İlaç etkileşimleri)

  • Desogestrel ve etinilestradioloral kontraseptifMinör

    If other contraceptive methods are not suitable, hormonal contraceptive therapy may continue combined with antihypertensive therapy. (Desogestrel ve etinilestradiol etiketi, Uyarılar)

  • DesonidkortikosteroidMinör

    Corticosteroids, ACTH - Intensified electrolyte depletion, particularly hypokalemia. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (Dosetaksel etiketi, Uyarılar ve önlemler)

  • EfedrinsempatomimetikMinör

    Examples: α-adrenergic antagonists, β-adrenergic receptor antagonists, reserpine, quinidine, mephentermine Other Drug Interactions G u anethidine C linical Impact: Ephedrine may inhibit the neuron blockage produced by guanethidine, resulting in loss of antihypertensive effectiveness. (Efedrin etiketi, İlaç etkileşimleri)

  • In addition to discontinuation of the drug, diuretic therapy may be required. (Esterifiye östrojenler ve metiltestosteron etiketi, Uyarılar)

  • Febuksostatksantin oksidaz inhibitörüMinör

    In Vivo Drug Interaction Studies Based on drug interaction studies in healthy patients, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3) ]. (Febuksostat etiketi, İlaç etkileşimleri)

  • Finasterid5-alfa redüktaz inhibitörüMinör

    …PROSCAR was concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, α-blockers, angiotensin-converting enzyme (ACE) inhibitors, analgesics, anti-convulsants, beta-adrenergic blocking agents, diuretics, calcium channel blockers, cardiac nitrates, HMG-CoA reductase inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), benzodiazepines,… (Finasterid etiketi, İlaç etkileşimleri)

  • FingolimodimmünosüpresanMinör

    Drugs That Slow Heart Rate or Atrioventricular Conduction (e.g., beta blockers or diltiazem) Experience with GILENYA in patients receiving concurrent therapy with drugs that slow the heart rate or AV conduction (e.g., beta blockers, digoxin, or heart rate-slowing calcium channel blockers, such as diltiazem or verapamil) is limited. (Fingolimod etiketi, İlaç etkileşimleri)

  • FlunisolidkortikosteroidMinör

    Corticosteroids, ACTH - Intensified electrolyte depletion, particularly hypokalemia. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • FluosinonidkortikosteroidMinör

    Corticosteroids, ACTH - Intensified electrolyte depletion, particularly hypokalemia. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • FlutikazonkortikosteroidMinör

    Corticosteroids, ACTH - Intensified electrolyte depletion, particularly hypokalemia. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • HalobetazolkortikosteroidMinör

    Corticosteroids, ACTH - Intensified electrolyte depletion, particularly hypokalemia. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • HidrokortizonkortikosteroidMinör

    Corticosteroids, ACTH - Intensified electrolyte depletion, particularly hypokalemia. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • ACE Inhibitors FIRAZYR is a bradykinin B2 receptor antagonist and thereby has the potential to have a pharmacodynamic interaction with ACE inhibitors where FIRAZYR may attenuate the antihypertensive effect of ACE inhibitors. (İkatibant etiketi, İlaç etkileşimleri)

  • İmatinibCYP3A4 inhibitörüMinör

    Weigh patients regularly and manage unexpected rapid weight gain by drug interruption and diuretics. (İmatinib etiketi, Uyarılar ve önlemler)

  • İpratropiumantikolinerjikMinör

    A beta 2 agonist (bronchodilator) should be made available. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • İzoprenalinbeta adrenerjik agonistMinör

    A beta 2 agonist (bronchodilator) should be made available. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • KalsiyumVitamin ve mineralMinör

    Tiyazid diüretikler kalsiyum atılımını azaltır; bu nedenle yüksek kalsiyum alımı kandaki kalsiyumu yükseltebilir. (NIH Office of Dietary Supplements, Calcium)

  • Drugs that may cause hypercalcemia: Vitamin D, vitamin A, thiazide diuretics, estrogen, calcipotriene and teriparatide administration may cause hypercalcemia. (Kalsiyum glukonat etiketi, İlaç etkileşimleri)

  • KlobetazolkortikosteroidMinör

    Corticosteroids, ACTH - Intensified electrolyte depletion, particularly hypokalemia. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Acthar Gel may accentuate the electrolyte loss associated with diuretic therapy. (Kortikotropin etiketi, İlaç etkileşimleri)

  • MagnezyumVitamin ve mineralMinör

    Kıvrım (loop) diüretiklerinin ve tiyazid diüretiklerin uzun süreli kullanımı idrarla magnezyum kaybını artırır. (NIH Office of Dietary Supplements, Magnesium)

  • Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (Masitentan etiketi, Uyarılar ve önlemler)

  • MetilprednizolonkortikosteroidMinör

    Corticosteroids, ACTH - Intensified electrolyte depletion, particularly hypokalemia. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • MetiltestosteronandrojenMinör

    In addition to discontinuation of the drug, diuretic therapy may be required. (Metiltestosteron etiketi, Uyarılar)

  • MilrinonPDE3 inhibitörüMinör

    …been observed in limited experience with patients in whom milrinone was used concurrently with the following drugs: digitalis glycosides; lidocaine, quinidine; hydralazine, prazosin; isosorbide dinitrate, nitroglycerin; chlorthalidone, furosemide, hydrochlorothiazide, spironolactone; captopril; heparin, warfarin, diazepam, insulin; and potassium supplements. (Milrinon etiketi, İlaç etkileşimleri)

  • Mirabegronbeta adrenerjik agonistMinör

    A beta 2 agonist (bronchodilator) should be made available. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • MometazonkortikosteroidMinör

    Corticosteroids, ACTH - Intensified electrolyte depletion, particularly hypokalemia. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Nortriptilintrisiklik antidepresanMinör

    The antihypertensive action of guanethidine and similar agents may be blocked. (Nortriptilin etiketi, Uyarılar)

  • Olopatadin ve mometazonantihistaminikMinör

    Corticosteroids, ACTH - Intensified electrolyte depletion, particularly hypokalemia. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • PerfenazinantipsikotikMinör

    Drug Interactions Metabolism of a number of medications, including antipsychotics, antidepressants, β-blockers, and antiarrhythmics, occurs through the cytochrome P450 2D6 isoenzyme (debrisoquine hydroxylase). (Perfenazin etiketi, İlaç etkileşimleri)

  • PotasyumVitamin ve mineralMinör

    Kıvrım (loop) diüretikleri ve tiyazid diüretikler potasyum kaybını artırır; bazen bunlarla birlikte takviye reçete edilir. (NIH Office of Dietary Supplements, Potassium)

  • PrednizolonkortikosteroidMinör

    Corticosteroids, ACTH - Intensified electrolyte depletion, particularly hypokalemia. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • PrednizonkortikosteroidMinör

    Corticosteroids, ACTH - Intensified electrolyte depletion, particularly hypokalemia. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • Protriptilintrisiklik antidepresanMinör

    Protriptyline may block the antihypertensive effect of guanethidine or similarly acting compounds. (Protriptilin etiketi, Uyarılar)

  • SiklesonidkortikosteroidMinör

    Corticosteroids, ACTH - Intensified electrolyte depletion, particularly hypokalemia. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • TeofilinmetilksantinMinör

    A beta 2 agonist (bronchodilator) should be made available. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • TerbinafinantifungalMinör

    Drugs predominantly metabolized by the CYP450 2D6 isozyme include the following drug classes: tricyclic antidepressants, selective serotonin reuptake inhibitors, beta-blockers, antiarrhythmics class 1C (e.g., flecainide and propafenone) and monoamine oxidase inhibitors Type B. (Terbinafin etiketi, İlaç etkileşimleri)

  • Timololbeta blokerMinör

    Bisoprolol fumarate and hydrochlorothiazide tablets should not be combined with other beta-blocking agents. (Bisoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

  • TiotropiumantikolinerjikMinör

    A beta 2 agonist (bronchodilator) should be made available. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • TriamsinolonkortikosteroidMinör

    Corticosteroids, ACTH - Intensified electrolyte depletion, particularly hypokalemia. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

  • UmeklidinyumantikolinerjikMinör

    A beta 2 agonist (bronchodilator) should be made available. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • Vibegronbeta adrenerjik agonistMinör

    A beta 2 agonist (bronchodilator) should be made available. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

Anlamlı etkileşim olmadığı bildirilenler (3)

  • PamidronatbifosfonatEtkileşim yok

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (Pamidronat etiketi, İlaç etkileşimleri)

  • Ropiniroldopamin agonistiEtkileşim yok

    Commonly Administered Drugs: Population analysis showed that commonly administered drugs (e.g., selegiline, amantadine, tricyclic antidepressants, benzodiazepines, ibuprofen, thiazides, antihistamines, anticholinergics) did not affect the clearance of ropinirole. (Ropinirol etiketi, İlaç etkileşimleri)

  • SimetidinH2 blokeriEtkileşim yok

    Pharmacokinetic studies document no clinically relevant interactions with other agents given concomitantly, including thiazide diuretics and cimetidine. (Bisoprolol ve hidroklorotiyazid etiketi, Önlemler)

Kullandığınız her şeyi Bisoprolol ve hidroklorotiyazid ile karşılaştırın. Tüm listenizi ekleyin; her çift tek seferde kontrol edilir.

Sorgulama aracında aç

Tıbbi tavsiye değildir. Şiddet derecesi sizin koşullarınızı değil, etiketin ifadesini yansıtır. “Majör” işareti gözetim altında olağan bir uygulama olabilir, “minör” işareti ise yüksek dozlarda önem kazanabilir. Bir eczacıya danışın.